Fetal Bovine Serum Global Market Report 2021: COVID-19 Growth And Change

Fetal Bovine Serum Global Market Report 2021: COVID-19 Growth And Change

  • July 2021 •
  • 175 pages •
  • Report ID: 6103736 •
  • Format: PDF
Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc., Biowest, Bio-Techne, Rocky Mountain Biologicals Inc., Merck KGaA, TCS Biosciences Ltd, Bovogen Biologicals Pty Ltd, Tissue Culture Biologicals, Atlanta Biologicals Inc., Atlas Biologicals, Acess Biologicals, Animal Technologies Inc, Nucleus Biologics, Corning Incorporated, J R Scientific Inc., Cytiva, Axil Scientific Pte Ltd, and Moregate Biotech.

The global fetal bovine serum market is expected to grow from $855.80 million in 2020 to $946.25 million in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth in mainly due to increase in R&D towards development of novel biopharmaceuticals. The market is expected to reach $1,175.36 million in 2025 at a CAGR of 5.6%.

The fetal bovine serum market consists of sales of fetal bovine serum by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing fetal bovine serum and related services.Fetal bovine serum refers to the liquid fraction of clotted blood from fetal calves, with reduced cells, fibrin, and clotting factors.

It has high concentration of nutritional and macromolecular factors essential for cell growth and is a critical raw material for animal care, biotechnology, drug development, diagnostics, and other fields of research.

The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others.Charcoal stripped fetal bovine serum has activated carbon that helps lower levels of lipophilic compounds such as hormones, growth factors, and steroids and is used to conduct receptor or estrogen related studies.

Dialyzed fetal bovine serum has reduced concentration of low molecular weight components such as nucleotides, amino acids, hormones, salts and various small proteins in serum and is used in cell culture systems requiring a more defined environment of small molecules.Exosome depleted fetal bovine serum isolates exosomes from cultured cells without the complication of bovine exosomes that are present in conventional FBS and is used for research on exosomes.

The fetal bovine serum is used in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, others. Fetal bovine serum is used in various sectors including research and academic institutes, biotechnology and pharmaceutical industry, others.

North America was the largest region in the fetal bovine serum market in 2020.Asia Pacific recorded the fastest growth during the forecast period.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Increasing collaborations between companies and research intuitions is a key trend gaining popularity in the fetal bovine serum market.Major companies are collaborating for increasing production capabilities, expanding market share and developing new products.

For instance, in 2017, US based GE Healthcare collaborated with New Zealand based Oritain for developing an independent test that can confirm the country of origin of fetal bovine serum (FBS) which would help biomanufacturing entities as FBS used in different countries pose different risk levels for virus contamination.

In December 2019, Sartorius, a German-based life science research and biopharmaceutical company acquired Biological Industries for $53.67 million. Through this acquisition, Sartorius expanded cell culture media and complementing the product portfolio for the users in the growing advanced therapies market in the majority portion of Biological Industries. Biological Industries is an Israel-based chemical and biotechnology company that provides fetal bovine serum for mammalian cell culture.

The increasing demand for biopharmaceuticals is expected to drive the growth of the fetal bovine serum market in the forecast period.A biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology.

Fetal bovine serum (FBS) is the most widely used substitute for animal cell culture media.Pharmaceutical firms, diagnostic laboratories, and researchers rely heavily on FBS for much of their cell culture requirements in biologics research.

The global biologics market is expected to increase from $253.4 billion in 2020 to $420.5 billion by 2025. Therefore, the rising demand for biopharmaceuticals propels the growth of the fetal bovine serum market.

The countries covered in the Fetal Bovine Serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.